

Ref CRC: 099-96

July 20, 2020

Collaborative Research Agreement
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health
And
Cardiovascular Research Center, Health Institute, Kermanshah University of Medical Sciences

Main Project: Prospective evaluation of urinary biomarkers of tobacco-related exposures in relation to incident cancer, and deaths due to cardiac and respiratory diseases in the Golestan Cohort Study

Current Study: The association of VOCs and nicotine metabolites with cardiovascular disease; a case-cohort study

Project period: from July 01, 2020 to June 30, 2021

Specific responsibility of each organization will be as follow:

National Cancer Institute:

- 1- Measuring 39 tobacco biomarkers to evaluate levels of nicotine metabolites and VOCs in urine samples of 1500 case and control participants.
- 2- Evaluating the validity of self-reported tobacco assessment.
- 3- Providing methodological and statistical consultation during preparing the manuscript.
- 4- Fully supervising the first author, Dr. Mahdi Nalini, to write the final report
- 5- Preparing authorship list and appropriate journal to submission

Cardiovascular Research Center:

- 1- Preparing statistical analyses under NCI supervision
- 2- Writing the first draft of the manuscript under NCI supervision
- 3- Providing periodical reports on the status of the project

NCI representative



Arash Etemadi, MD PhD
Staff Scientist,
Division of Cancer Epidemiology and Genetics,
National Cancer Institute, NIH
Bethesda, MD 20850, USA
Phone: 240-276-7197
Email: arash.etemadi@nih.gov

Cardiovascular Research Center representative



Nahid Salehi, MD
Director, Cardiovascular Research Center,
Kermanshah University of Medical Sciences,
Kermanshah, Iran
Phone: 0912 203 5001
Email: n_salehi45@yahoo.com